ClinicalTrials.gg
TerminatedNCT05171049ASTERUpdated Feb 23, 2026

A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE

A Phase 3 interventional study of Abelacimab and Apixaban in Venous Thromboembolism, Deep Venous Thrombosis and Pulmonary Embolism, sponsored by Anthos Therapeutics, Inc.. Terminated at 209 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-23.

Sponsored by Anthos Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Why this study was terminated
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 74 studies in Venous Thromboembolism with a site in Italy — 10 open to participants now, 13 under way, 3 of them phase 3. Venous Thromboembolism · Italy.

Enrollment
22nd of 50
1,150 · median 839
Started
2022
with 1 other
Phase 3
32 of 74
3 open now
Registered
63rd of 74
by date

Among the 74 studies in Venous Thromboembolism with a site in Italy, this one is the 22nd largest by enrollment of the 50 interventional ones that give a count, is one of 2 that started in 2022, is one of 32 in phase 3, and was the 63rd registered.

Venous Thromboembolism

713 studies on the registry are indexed under Venous Thromboembolism; 147 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

10 of the 74 studies in Venous Thromboembolism with a site in Italy are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 113 Venous Thromboembolism studies recruiting now, 90 (80%) set no upper age limit and 13 (12%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies in Venous Thromboembolism with a site in Italy, or all of them as a file.
02

Study summary

This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)

Read the detailed description

Cancer associated thrombosis (CAT) is a severe medical condition which is characterized by high incidence of Venous thromboembolism (VTE) recurrence and high risk for bleeding. The two most common treatments today are low molecular weight heparin (LMWH) and direct anticoagulants (DOACs), in which each has limitations. DOACs are administered orally and are seen as a more convenient alternative though associated with bleeding risk; further, some cancer patients have difficulty swallowing or develop vomiting which leads to unpredictable pharmacodynamic effects with oral therapy. The ANT-007 study will compare treatment with abelacimab monthly administration to apixaban twice daily administration over a 6-month treatment. The study outcomes include VTE recurrence, bleeding event and treatment discontinuation at 6 months

03

Conditions studied

  • Venous Thromboembolism
  • Deep Venous Thrombosis
  • Pulmonary Embolism

Keywords

  • Anticoagulants
  • VTE recurrence rate
  • PROBE design
  • LMWH
  • CAT
  • Cancer associated VTE
  • Abelacimab
  • Apixaban
  • FXI
  • Major bleeding events
  • CRNM bleeding events
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects ≥18 years old or other legal maturity age according to the country of residence
  • Confirmed diagnosis of cancer (by histology, adequate imaging modality), other than basal-cell or squamous-cell carcinoma of the skin alone with one of the following:

    • Active cancer, defined as either locally active, regionally invasive, or cancer at the time of randomization and/or
    • Currently receiving or having received anticancer therapy (radiotherapy, chemotherapy, hormonal therapy, any kind of targeted therapy or any other anticancer therapy) in the last 6 months.
  • Confirmed symptomatic or incidental proximal lower limb deep vein thrombosis (DVT) (i.e., popliteal, femoral, iliac, and/or inferior vena cava [IVC] thrombosis) and/or a confirmed symptomatic pulmonary embolism (PE), or an incidental PE in a segmental, or larger pulmonary artery.

Patients are eligible within 120 hours from diagnosis of the qualifying VTE

  • Anticoagulation therapy with a therapeutic dose of DOAC for at least 6 months is indicated
  • Able to provide written

Exclusion criteria

Exclusion Criteria:

  • Thrombectomy, insertion of a caval filter or use of a fibrinolytic agent to treat the current (index) DVT and/or PE
  • More than 120 hours of pre-treatment with therapeutic doses of UFH, LMWH, fondaparinux, DOAC, or other anticoagulants
  • An indication to continue treatment with therapeutic doses of an anticoagulant other than that VTE treatment prior to randomization (e.g., atrial fibrillation [AF], mechanical heart valve, prior VTE)
  • count \<50,000/mm3 at the screening visit
  • PE leading to hemodynamic instability (blood pressure [BP] \<90 mmHg or shock)
  • Acute ischemic or hemorrhagic stroke or intracranial hemorrhage within the 4 weeks preceding screening
  • Brain trauma or a cerebral or spinal cord surgery or spinal procedures such as lumbar puncture or epidural/spinal anesthesia within 4 weeks of screening
  • Need for aspirin in a dosage of >100 mg/day or any other antiplatelet agent alone or in combination with aspirin
  • Primary brain cancer or untreated intracranial at baseline
  • Acute myeloid or lymphoid leukemia
  • Bleeding requiring medical attention at the time of randomization or in the preceding 4 weeks
  • Planned brain, spinal cord, cardiac, vascular, major thoracic and/or major abdominal surgery in the 4 weeks following randomization
  • (ECOG) performance status of 3 or 4 at screening
  • \<3 months at randomization
  • Calculated (CrCl) \<30 mL/min (Cockcroft-Gault equation) at the screening visit
  • \<8 g/dL at the screening visit
  • Acute hepatitis, chronic active hepatitis, liver cirrhosis; or an (ALT) ≥3 x and/or ≥2 x (ULN) at the screening visit in absence of clinical explanation
  • Uncontrolled hypertension (systolic BP>180 mm Hg or diastolic BP >100 mm Hg despite antihypertensive treatment)
  • Women of (WOCBP) who are unwilling or unable to use highly effective measures during the study from screening up to 3 days after last treatment of apixaban or 100 days after administration of abelacimab (See Section 5.3.6. for highly effective contraceptive measures)
  • Sexually active males with sexual partners of childbearing potential must agree to use a condom or other reliable contraceptive measure up to 3 days after last treatment of apixaban or 100 days after administration of abelacimab
  • Pregnant or breast-feeding women
  • Patients known to be receiving strong dual inducers or inhibitors of both and P gp
  • History of to any of the study drugs (including apixaban) or , to drugs of similar chemical classes, or any listed in the label for apixaban
  • Subjects with any condition that in the Investigator's judgement would place the subject at increased risk of harm if he/she participated in the study
  • Use of other (not registered) drugs within 5 half-lives prior to enrollment or until the expected pharmacodynamic(s) (PD) effect has returned to baseline, whichever is longer. Participation in academic non-interventional studies or interventional studies, comprising testing different strategies or different combinations of registered drugs is permitted
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,150 participants (actual)

Study arms

  • Experimental
    Abelacimab

    Abelacimab intravenous administration followed by monthly administration of the same dose subcutaneously

    Biological: Abelacimab

  • Active comparator
    Apixaban

    Apixaban administered orally twice a day

    Drug: Apixaban

Interventions

  • BiologicalAbelacimab

    Abelacimab 150 mg

    Also known as: MAA868

  • Apixaban 10 mg followed by 5 mg

    Also known as: Eliquis

06

What researchers measure

Primary outcomes

  1. Time to first event of centrally adjudicated VTE recurrence

    Time to first event of centrally adjudicated venous thromboembolism (VTE) recurrence

    Time frame: Up to 6 months

Secondary outcomes

  1. Time to first event of ISTH-adjudicated major or clinically relevant non-major (CRNM) bleeding events

    Time to first adjudicated major or clinically relevant non-major (CRNM) bleeding event

    Time frame: Up to 6 months

  2. Time to first event of VTE recurrence, ISTH adjudicated major or ISTH-adjudicated clinically relevant non-major (CRNM) bleeding events

    Time to first adjudicated venous thromboembolism (VTE) or bleeding event

    Time frame: Up to 6 months

  3. Time to event of permanent treatment discontinuation not due to death

    Time to permanent discontinuation not due to death

    Time frame: Up to 6 months

  4. Time to first event of ISTH-adjudicated clinically relevant non-major (CRNM) bleeding events

    Time to first adjudicated clinically relevant non-major (CRNM) bleeding event

    Time frame: Up to 6 months

  5. Time to first event of ISTH-adjudicated major bleeding events

    Time to first adjudicated major bleeding event

    Time frame: Up to 6 months

  6. Time to first event of GI ISTH-adjudicated major and CRNM bleeding events

    Time to first adjudicated gastrointestinal (GI) major and clinically relevant non-major (CRNM) bleeding event

    Time frame: Up to 6 months

  7. All-cause death, vascular death, serious adverse events, adverse events leading to drug discontinuation, other adverse events, abnormal lab tests, etc. presented as rate per 100 patient-years

    Time frame: Up to 6 months

  8. For patients treated with abelacimab: percent with injection site reactions/severity, hypersensitivity reactions/severity, anti-drug antibody formation, neutralizing antibody

    Time frame: Up to 6 months

07

Study locations

209 sites
  • University of Colorado Anschutz Medical Campus
    Aurora, Colorado 80045, United States
  • VA Connecticut Healthcare System
    West Haven, Connecticut 06516-5907, United States
  • Washington DC VAMC
    Washington D.C., District of Columbia 20422, United States
  • University of Miami Health
    Miami, Florida 33136, United States
  • NorthShore University Health System
    Evanston, Illinois 60201, United States
  • University of Kentucky, Markey Cancer Center
    Lexington, Kentucky 40536-0093, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215-5400, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Washington University
    St Louis, Missouri 63110, United States
  • Memorial Sloan Kettering Cancer Center-Middletown
    Middletown, New Jersey 07748, United States
  • Memorial Sloan Kettering Cancer Center-Commack
    Commack, New York 11725, United States
  • Memorial Sloan Kettering Cancer Center-West Harrison
    Harrison, New York 10604, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10021-0005, United States
  • Lipson Cancer Institute
    Rochester, New York 14621, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • University of Pennsylvania - Penn Blood Disorders Center
    Philadelphia, Pennsylvania 19104, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • University of Texas Mays Cancer Center
    San Antonio, Texas 78229, United States
  • Gundersen Health System
    La Crosse, Wisconsin 54601, United States
  • Blood Center of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Blacktown Hospital
    Blacktown, New South Wales 2148, Australia
  • Concord Repatriation General Hospital
    Concord, New South Wales 2139, Australia
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • Box Hill Hospital
    Box Hill, Victoria 3128, Australia
  • Monash Medical Centre Clayton
    Clayton, Victoria 3168, Australia
  • Northern Health
    Epping, Victoria 3076, Australia
  • Perth Blood Institute
    Perth, 6005, Australia
  • The Alfred Hospital
    Prahran, 3181, Australia
  • LKH - Universitätsklinikum Graz
    Graz, 8010, Austria
  • LK Wiener Neustadt
    Neustadt, 2700, Austria
  • Medical University of Vienna
    Vienna, 1090, Austria
  • University of Calgary
    Calgary, Alberta T2N 1N4, Canada
  • University of Alberta Hospital
    Edmonton, Alberta T6G2V2, Canada
  • Hamilton Health Sciences, Juravinski Hospital and Cancer Centre
    Hamilton, Ontario L8V 1C3, Canada
  • Ottawa Hospital
    Ottawa, Ontario K1H BL6, Canada
  • Niagara Health System
    Saint Catharines, Ontario L2S 0A9, Canada
  • Sault Area Hospital
    Sault Ste. Marie, Ontario P6A 0A8, Canada
  • Toronto General Hospital
    Toronto, Ontario M5G 2C4, Canada
  • Jewish General Hospital
    Montreal, Quebec H3T-1E2, Canada
  • McGill University Health Centre
    Montreal, Quebec H4A 3J1, Canada
  • Queen Elizabeth II Health Sciences Centre
    Nova Scotia, B3H 2Y9, Canada
  • McGill University Health Centre
    Québec, H4A 3J1, Canada
  • Beijing Shijitan Hosp.
    Beijing, 100038, China
  • Peking University Third Hospital
    Beijing, 100191, China
  • Jilin Province Tumor Hospital
    Ch’ang-ch’un, 130012, China
  • Southern Medical University - Zhujiang Hospital
    Guangdong, 510280, China
  • Nanfang Hospital of Southern Medical University
    Guangzhou, 510515, China
  • The Sixth Affiliated Hospital of Sun Yat-Sen University
    Guangzhou, 510655, China
  • Huizhou Municipal Central Hospital
    Huizhou, 516001, China
  • Nanjing First Hospital
    Nanjing, 210006, China
  • Jiangsu Province Hospital
    Nanjing, 210029, China
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, 325000, China
  • Union Hospital Tongji Medical College Huazhong University of Science &Technology
    Wuhan, 430023, China
  • Tongji Hospital, Tongji Medical College
    Wuhan, 430030, China
  • 1st Affiliate Hospital of Xi'an Jiao
    Xi'an, 710061, China
  • Masarykuv onkologicky ustav
    Brno, 65653, Czechia
  • University Hospital Hradec Kralove
    Hradec Králové, 50005, Czechia
  • Nemocnice Na Pleši s.r.o.
    Nová Ves pod Pleší, 26204, Czechia
  • Onkologická klinika VFN a 1. LF UK
    Prague, 128 08, Czechia
  • Thomayerova nemocnice
    Prague, 14059, Czechia
  • CHU Amiens - Hopital Nord
    Amiens, 80057, France
  • CHU Angers - Hôpital Hôtel Dieu
    Angers, 49933, France
  • CHU de Brest - Hôpital de la Cavale Blanche
    Brest, 29609, France
  • CHU Clermont Ferrand - Hopital Gabriel Montpied
    Clermont-Ferrand, 63003, France
  • Hôpital Louis Mourier
    Colombes, 92700, France
  • CHU Dijon - Hôpital Bocage Central
    Dijon, 21079, France
  • CHU de Grenoble - Hôpital Albert Michallon
    Grenoble, 38043, France
  • CH Le Puy en Velay
    Le Puy-en-Velay, 43000, France
  • CHU de Limoges - Hôpital Dupuytren
    Limoges, 87042, France
  • Hopital Timone Adultes
    Marseille, 13385, France
  • Centre hospitalier des pays de Morlaix
    Morlaix, 29600, France
  • Hôpital Européen Georges Pompidou
    Paris, 75015, France
  • Groupe Hospitalier Pitie-Salpetriere
    Paris, 75651, France
  • Hospices Civils de Lyon (HCL) - Centre Hospitalier Lyon-Sud
    Pierre-Bénite, 69310, France
  • CHU de Rouen - Hôpital de Bois Guillaume
    Rouen, 76031, France
  • CHU de Saint-Etienne - Hopital Nord
    Saint-Etienne, 42000, France
  • CHU Strasbourg - Nouvel Hôpital Civil
    Strasbourg, 67091, France
  • Nouvel Hôpital Civil de Strasbourg
    Strasbourg, 67091, France
  • Centre Hospitalier Intercommunal de Toulon
    Toulon, 83000, France
  • CHU de Toulouse - Hôpital Rangueil
    Toulouse, 31059, France
  • CHU de Nancy - Hôpital de Brabois Adultes
    Vandœuvre-lès-Nancy, 54500, France
  • CHU de Nancy - Hôpital de Brabois Adultes
    Vandœuvre-lès-Nancy, 54511, France
  • Staedtisches Klinikum Dresden Standort Dresden-Friedrichstadt
    Dresden, 1067, Germany
  • Universitaetsklinikum Carl Gustav Carus TU Dresden
    Dresden, 1307, Germany
  • Praxis für Gefäßmedizin
    Görlitz, 2827, Germany
  • Universitaetsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Universitätsklinik der Christian-Albrechts-Universität
    Kiel, 24105, Germany
  • Universitätsklinik Leipzig
    Leipzig, 4103, Germany
  • Universitaetsklinikum Magdeburg A.oe.R
    Magdeburg, 39120, Germany
  • Klinikum der Universitaet Muenchen
    München, 80336, Germany
  • Debreceni Egyetem
    Debrecen, H-4032, Hungary
  • Markhot Ferenc Oktatokorhaz es Rendelointezet
    Eger, H-3300, Hungary
  • Bacs-Kiskun County Hospital
    Kecskemét, 6000, Hungary
  • Bon Secour Hospital
    Cork, Ireland
  • Cork University Hospital
    Cork, Ireland
  • Beaumont Hospital
    Dublin, V2N0, Ireland
  • Msdyrt Midericordiae University Hospital
    Dublin, Ireland

Showing the first 100 of 209 sites across 21 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in Feb 2026, 44 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2021
First posted
Dec 28, 2021
StartActual
May 5, 2022
Primary completionActual
Feb 4, 2026
CompletionActual
Feb 4, 2026
Last update
Feb 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05171049
Lead sponsor
Anthos Therapeutics, Inc.
Responsible party
Sponsor
First posted
Dec 28, 2021
Start date
May 5, 2022
Primary completion
Feb 4, 2026
Completion
Feb 4, 2026
Last update
Feb 23, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abelacimab

Start the discussion